| Literature DB >> 35344533 |
Rachael C Heath Jeffery1,2, Jennifer A Thompson3, Johnny Lo4, Tina M Lamey1,3, Terri L McLaren1,3, John N De Roach1,3, Dimitar N Azamanov5, Ian L McAllister1, Ian J Constable1, Fred K Chen1,2,6.
Abstract
PURPOSE: To investigate concordance in symptom onset, area of dark autofluorescence (DAF), and growth rate (GR) between Stargardt disease siblings at an age-matched time point.Entities:
Mesh:
Substances:
Year: 2022 PMID: 35344533 PMCID: PMC9301984 DOI: 10.1097/IAE.0000000000003477
Source DB: PubMed Journal: Retina ISSN: 0275-004X Impact factor: 3.975
Baseline Demographics and Discordance in Age at Symptom Onset
| Family No. | Genotype Class | Patient No. | Year of Birth | Sex | Age at Symptom Onset (years) | Discordance in Symptom Onset (years) | Age at Baseline Examination (years) | Age at Final Examination (years) | Duration of Disease at Baseline (years) | Duration of Follow-Up (years) | Age-Matching during Follow up (Age of Siblings) |
| F1 | B | P1 | 1983 | M | 17 | 1 | 29 | 36 | 12 | 7.04 | Yes (29, 30) |
| P2 | 1985 | M | 16 | 25 | 34 | 9 | 8.51 | ||||
| F2 | B | P3 | 1986 | F | 15 | 4 | 30 | 33 | 15 | 3.67 | Yes (30, 30) |
| P4 | 1988 | M | 19 | 24 | 31 | 5 | 7.21 | ||||
| F3 | A | P5 | 1977 | F | 10 | 3 | 39 | 41 | 29 | 2.67 | Yes (38, 39) |
| P6 | 1982 | M | 7 | 29 | 38 | 22 | 8.72 | ||||
| F4 | B | P7 | 1958 | M | 7 | 1 | 57 | 62 | 50 | 5.14 | Yes, (58, 58) |
| P8 | 1960 | M | 6 | 58 | 60 | 52 | 1.48 | ||||
| F5 | B | P9 | 1961 | F | 36 | 15 | 55 | 59 | 19 | 3.66 | Yes (57, 57) |
| P10 | 1959 | M | 51 | 57 | 61 | 6 | 4.51 | ||||
| F6 | A | P11 | 2001 | M | 9 | 2 | 12 | 19 | 4 | 6.25 | Yes (12, 12) |
| P12 | 2006 | M | 11 | 6 | 14 | −5 | 3.16 | ||||
| F7 | A | P13 | 2003 | M | 7 | 1 | 15 | 18 | 8 | 2.53 | Yes (18, 18) |
| P14 | 1994 | F | 6 | 18 | 26 | 12 | 7.76 | ||||
| F8 | C | P15 | 1992 | F | 18 | 4 | 21 | 28 | 3 | 6.73 | Yes (23, 23) |
| P16 | 1990 | F | 22 | 23 | 29 | 1 | 6.24 | ||||
| F9 | C | P17 | 1958 | M | 62 | 35 | 58 | 62 | −4 | 7.81 | No |
| P18 | 1967 | F | 27 | 48 | 53 | 21 | 5.27 | ||||
| F10 | B | P19 | 1937 | M | 22 | 14 | 75 | 79 | 53 | 3.55 | Yes (75, 75) |
| P20 | 1942 | F | 8 | 73 | 78 | 65 | 5.27 | ||||
| F11 | B | P21 | 1971 | M | 13 | 1, 3, 4 | 40 | 49 | 27 | 8.61 | Yes (40, 41) |
| P22 | 1977 | M | 12 | 41 | — | 29 | — | ||||
| P23 | 1969 | F | 16 | — | — | — | — | ||||
| F12 | A | P24 | 1963 | F | 9 | 3 | 53 | 57 | 44 | 4.79 | No |
| P25 | 1971 | F | 12 | 44 | 48 | 32 | 4.11 | ||||
| F13 | C | P26 | 1979 | F | 15 | 0 | 38 | 39 | 23 | 1.18 | Yes (37, 38) |
| P27 | 1982 | F | 15 | 35 | 37 | 20 | 1.18 | ||||
| F14 | A | P28 | 1993 | F | 8 | 1 | 27 | 28 | 19 | 0.51 | Yes (26, 27) |
| P29 | 1994 | M | 9 | 25 | 26 | 16 | 1.52 | ||||
| F15 | C | P30 | 1937 | M | 82 | 7 | 83 | 84 | 1 | 1.00 | No |
| P31 | 1942 | F | 75 | 75 | 78 | 0 | 3.16 | ||||
| F16 | B | P32 | 1990 | F | NA | NA | 30 | — | — | — | Yes (30, 30) |
| P33 | 1990 | F | 29 | 30 | — | 1 | — | ||||
| F17 | C | P34 | 1973 | M | 33 | 2 | 46 | — | 13 | — | No |
| P35 | 1978 | F | 31 | 42 | — | 11 | — | ||||
| F18 | B | P36 | 1971 | F | NA | >32 | 48 | 49 | — | 1.53 | No |
| P37 | 1976 | F | 17 | 44 | — | 27 | — | ||||
| F19 | C | P38 | 1994 | F | 16 | 0 | 25 | — | 9 | — | No |
| P39 | 1987 | F | 16 | — | — | — | — |
Definition: Class A, severe biallelic mutations. Class B, an allele of intermediate severity in trans with a severe or intermediate allele. Class C, a mild allele in trans with a severe allele.
NA, not applicable as patient remained asymptomatic at latest follow-up.
Comparison of Age-Matched Sibling Pairs' Best Corrected Visual Acuity and Atrophy Area
| Family No. | Genotype Class | Patient No. | Sex | Age at Symptom Onset (years) | Age at Examination (years) | Duration of Disease at Match (years) | Age-Matched Measurements | Inter-sibling Differences | Foveal Sparing | ||||||||||
| BCVA | DAF Area mm2 | DAF Radius, mm | BCVA | DAF Area, mm2 | DAF Radius, mm | ||||||||||||||
| Right | Left | Right | Left | Right | Left | Right | Left | Right | Left | Right | Left | ||||||||
| F1 | B | P1 | M | 17 | 29 | 12 | 6 | 17 | 9.6 | 11.7 | 1.75 | 1.93 | 27 | 20 | 1.1 | 4.4 | 0.10 | 0.41 | No |
| P2 | M | 16 | 29 | 13 | 33 | 37 | 8.5 | 7.3 | 1.64 | 1.52 | No | ||||||||
| F2 | B | P3 | F | 15 | 30 | 15 | 35 | 35 | 0.6 | 0.8 | 0.44 | 0.50 | 6 | 7 | 0.8 | 1.5 | 0.23 | 0.35 | No |
| P4 | M | 19 | 30 | 11 | 41 | 42 | 1.4 | 2.3 | 0.67 | 0.86 | No | ||||||||
| F3 | A | P5 | F | 10 | 39 | 29 | 15 | 38 | 64.9 | 64.6 | 4.55 | 4.53 | 0 | 18 | 12.7 | 8.7 | 0.47 | 0.32 | No |
| P6 | M | 7 | 38 | 31 | 15 | 20 | 52.2 | 55.9 | 4.08 | 4.22 | No | ||||||||
| F4 | B | P7 | M | 7 | 58 | 51 | 9 | 8 | 74.4 | 73.4 | 4.87 | 4.83 | 6 | 6 | 23.0 | 29.0 | 0.82 | 1.07 | No |
| P8 | M | 6 | 58 | 52 | 3 | 2 | 51.4 | 44.4 | 4.04 | 3.76 | No | ||||||||
| F5 | B | P9 | F | 36 | 57 | 21 | 82 | 81 | 14.7 | 2.3 | 2.16 | 0.86 | 77 | 27 | 12.3 | 1.9 | 1.29 | 0.50 | No |
| P10 | M | 51 | 57 | 6 | 5 | 54 | 2.4 | 0.4 | 0.87 | 0.36 | No | ||||||||
| F6 | A | P11 | M | 9 | 12 | 3 | 15 | 17 | 0.2 | 0.4 | 0.25 | 0.36 | 55 | 58 | 0.2 | 0.4 | 0.25 | 0.36 | No |
| P12 | M | 11 | 12 | 1 | 70 | 75 | 0.0 | 0.0 | 0.00 | 0.00 | No | ||||||||
| F7 | A | P13 | M | 7 | 18 | 11 | 31 | 35 | 4.5 | 3.5 | 1.20 | 1.06 | 4 | 0 | 3.1 | 3.9 | 0.36 | 0.48 | No |
| P14 | F | 6 | 18 | 12 | 35 | 35 | 7.6 | 7.4 | 1.56 | 1.53 | No | ||||||||
| F8 | C | P15 | F | 18 | 23 | 5 | 68 | 69 | 0.0 | 0.0 | 0.00 | 0.00 | 14 | 14 | 0.0 | 0.0 | 0.00 | 0.00 | No |
| P16 | F | 22 | 23 | 1 | 82 | 83 | 0.0 | 0.0 | 0.00 | 0.00 | No | ||||||||
| F10 | B | P19 | M | 22 | 75 | 53 | −30 | −30 | 31.0 | 35.5 | 3.14 | 3.36 | 0 | 0 | 24.6 | 9.7 | 1.07 | 0.43 | No |
| P20 | F | 8 | 75 | 67 | −30 | −30 | 55.6 | 45.2 | 4.21 | 3.79 | No | ||||||||
| F11 | B | P21 | M | 13 | 40 | 27 | 20 | 30 | 24.2 | 20.7 | 2.78 | 2.57 | 7 | 4 | 3.3 | 5.9 | 0.20 | 0.40 | No |
| P22 | M | 12 | 41 | 29 | 27 | 26 | 20.9 | 14.8 | 2.58 | 2.17 | No | ||||||||
| F13 | C | P26 | F | 15 | 38 | 23 | 40 | 53 | 0.0 | 0.0 | 0.00 | 0.00 | 2 | 14 | 2.9 | 2.5 | 0.96 | 0.89 | No |
| P27 | F | 15 | 37 | 22 | 38 | 39 | 2.9 | 2.5 | 0.96 | 0.89 | No | ||||||||
| F14 | A | P28 | F | 8 | 27 | 19 | 5 | 10 | 6.6 | 6.9 | 1.45 | 1.48 | 1 | 5 | 1.4 | 3.1 | 0.15 | 0.30 | No |
| P29 | M | 9 | 26 | 17 | 4 | 5 | 8.0 | 10.0 | 1.60 | 1.78 | No | ||||||||
| F16 | B | P32 | F | NA | 30 | NA | 85 | 81 | 0.3 | 0.2 | 0.31 | 0.25 | 4 | 13 | 1.1 | 0.2 | 0.36 | 0.25 | No |
| P33 | F | 29 | 30 | 1 | 89 | 94 | 1.4 | 0.0 | 0.67 | 0.00 | No | ||||||||
Definition: Class A, severe biallelic mutations. Class B, an allele of intermediate severity in trans with a severe or intermediate allele. Class C, a mild allele in trans with a severe allele.
DAF, dark autofluorescence; NA, not applicable as patient remained asymptomatic at latest follow-up.
Comparison of Age-Matched Sibling Pairs' Atrophy Area and Effective Radius Growth Rates
| Family No. | Genotype Class | Patient No. | Sex | Age-Match (years) | Duration of Follow-Up (years) | Visual Acuity Change | Age-Matched Progression Rates in DAF | Inter-sibling Differences in DAF Growth | |||||||||
| Baseline | Final | Area Growth Rate (mm2/year) | Radius Growth Rate (mm/year) | Area Growth Rate (mm2/year) | Radius Growth Rate (mm/year) | ||||||||||||
| Right | Left | Right | Left | Right | Left | Right | Left | Right | Left | Right | Left | ||||||
| F1 | B | P1 | M | 29 | 7.04 | 6 | 17 | 5 | 19 | 3.27 | 3.12 | 0.21 | 0.19 | 1.117 | 1.233 | 0.009 | 0.0004 |
| P2 | M | 29 | 8.51 | 23 | 30 | 20 | 31 | 2.15 | 1.89 | 0.22 | 0.19 | ||||||
| F2 | B | P3 | F | 30 | 3.67 | 35 | 35 | 34 | 35 | 1.01 | 0.30 | 0.20 | 0.07 | 0.870 | 0.147 | 0.165 | 0.042 |
| P4 | M | 30 | 7.21 | 62 | 40 | 38 | 36 | 0.14 | 0.15 | 0.03 | 0.03 | ||||||
| F3 | A | P5 | F | 39 | 2.67 | 15 | 38 | 12 | 31 | 0.45 | 1.73 | 0.02 | 0.06 | 0.273 | 0.442 | 0.013 | 0.031 |
| P6 | M | 38 | 8.72 | 15 | 20 | 15 | 20 | 0.72 | 2.17 | 0.03 | 0.09 | ||||||
| F4 | B | P7 | M | 58 | 5.14 | 9 | 9 | 10 | 7 | 3.89 | 3.19 | 0.12 | 0.10 | 0.917 | 1.075 | 0.062 | 0.074 |
| P8 | M | 58 | 1.48 | 3 | 2 | 1 | 1 | 4.81 | 4.27 | 0.18 | 0.17 | ||||||
| F5 | B | P9 | F | 57 | 3.66 | 86 | 86 | 80 | 82 | 2.02 | 1.34 | 0.15 | 0.23 | 0.467 | 0.006 | 0.043 | 0.008 |
| P10 | M | 57 | 4.51 | 56 | 81 | −15 | 33 | 1.55 | 1.33 | 0.19 | 0.24 | ||||||
| F7 | A | P13 | M | 18 | 2.53 | 42 | 63 | 31 | 35 | 0.36 | 0.04 | 0.05 | 0.01 | 0.176 | 0.205 | 0.032 | 0.018 |
| P14 | F | 18 | 7.76 | 35 | 35 | 29 | 33 | 0.18 | 0.24 | 0.02 | 0.02 | ||||||
| F10 | B | P19 | M | 75 | 3.55 | −30 | −30 | −30 | −30 | 1.15 | 1.52 | 0.06 | 0.07 | 1.539 | 0.813 | 0.037 | 0.023 |
| P20 | F | 75 | 5.27 | −30 | −30 | −30 | −30 | 2.69 | 2.33 | 0.09 | 0.09 | ||||||
| F14 | A | P28 | F | 27 | 0.51 | 5 | 10 | 10 | 11 | 1.17 | 3.12 | 0.13 | 0.32 | 0.677 | 1.011 | 0.078 | 0.111 |
| P29 | M | 26 | 1.52 | 7 | 7 | 4 | 5 | 1.85 | 2.11 | 0.20 | 0.21 | ||||||
Definition: Class A, severe biallelic mutations. Class B, an allele of intermediate severity in trans with a severe or intermediate allele.
DAF, dark autofluorescence.
A Summary of Genetic Variants and Their Severities
| Family No. | Patient No. | Genotype Class | ||||||
| Allele 1 | Protein | Severity | Allele 2 | Protein | Severity | |||
| F1 | P1 | c.6079C>T | p.(Leu2027Phe) | Intermediate | c.768G>T | p.(Leu257Valfs*17) | Severe | B |
| P2 | ||||||||
| F2 | P3 | c.[2588G>C;5603A>T] | p.[Gly863Ala,Gly863del; Asn1868Ile] | mild1 | c.[5461–10T>C;5603A>T] | p.[Thr1821Valfs*13, Thr1821Aspfs*6] | Severe | B |
| P4 | ||||||||
| F3 | P5 | c.3617del | p.(Asn1206Metfs*3) | Severe | c.1496G>A | p.(Trp499*) | Severe | A |
| P6 | ||||||||
| F4 | P7 | c.4539+2028C>T | p.[=,Arg1514Leufs*36] | Intermediate | c.6031-6044delins18 | p.(Ile2003Leufs*41) | Severe | B |
| P8 | ||||||||
| F5 | P9 | c.6079C>T | p.(Leu2027Phe) | Intermediate | c.4577C>T | p.(Thr1526Met) | Severe | B |
| P10 | ||||||||
| F6 | P11 | c.[5461–10T>C;5603A>T] | p.[,Thr1821Valfs*13, Thr1821Aspfs*6] | Severe | c.4320del | p.(Phe1440Leufs*6) | Severe | A |
| P12 | ||||||||
| F7 | P13 | c.4919G>A | p.(Val1617_Arg1640del, Arg1640Gln) | severe3 | c.4919G>A | P.(Val1617_Arg1640del, Arg1640Gln) | severe3 | A |
| P14 | ||||||||
| F8 | P15 | c.5691G>T | p.(Gln1897His) | Mild | c.768G>T | p.(Leu257Valfs*17) | Severe | C |
| P16 | ||||||||
| F9 | P17 | c.3113C>T | p.(Ala1038Val) | Mild | c.2564G>A | p.(Trp855*) | Severe | C |
| P18 | ||||||||
| F10 | P19 | c.5537T>A | p.(Ile1846Asn) | Intermediate | c.[240_241del;5908C>T] | p.(Cys81Phefs*17) | Severe | B |
| P20 | ||||||||
| F11 | P21 | c.6079C>T | p.(Leu2027Phe) | Intermediate | c.4577C>T | p.(Thr1526Met) | Severe | B |
| P22 | ||||||||
| P23 | ||||||||
| F12 | P24 | c.3259G>A | p.(Glu1087Lys) | Severe | c.3190G>A | p.(Gly1064Ser) | Severe | A |
| P25 | ||||||||
| F13 | P26 | c.5882G>A | p.(Gly1961Glu) | Mild | c.4320del | p.(Phe1440Leufs*6) | Severe | C |
| P27 | ||||||||
| F14 | P28 | c.1574T>C | p.(Phe525Ser) | Severe | c.1906C>T | p.(Gln636*) | Severe | A |
| P29 | ||||||||
| F15 | P30 | c.5603A>T | p.(Asn1868Ile) | Mild | c.2894A>G | p.(Asn965Ser) | Severe | C |
| P31 | ||||||||
| F16 | P32 | c.1805G>A | p.(Arg602Gln) | Intermediate | c.4577C>T | p.(Thr1526Met) | Severe | B |
| P33 | ||||||||
| F17 | P34 | c.5882G>A | p.(Gly1961Glu) | Mild | c.4577C>T | p.(Thr1526Met) | Severe | C |
| P35 | ||||||||
| F18 | P36 | c.[2588G>C;5603A>T] | p.[Gly863Ala,Gly863del; Asn1868Ile] | Intermediate | c.634C>T | p.(Arg212Cys) | Intermediate | B |
| P37 | ||||||||
| F19 | P38 | c.6089G>A | p.(Arg2030Gln) | Mild | c.3407G>A | p.(Gly1136Glu) | Severe | C |
| P39 | ||||||||
Definition: Class A, severe biallelic mutations. Class B, an allele of intermediate severity in trans with a severe or intermediate allele. Class C, a mild allele in trans with a severe allele.
c.6031_6044delinsAGTATTTAACCAATATTT.
References.
1. Sangermano, R., et al, ABCA4 midigenes reveal the full splice spectrum of all reported noncanonical splice site variants in Stargardt disease. Genome Res, 2018. 28(1): p. 100-110.
2. Fakin, A., et al, The Effect on Retinal Structure and Function of 15 Specific ABCA4 Mutations: A Detailed Examination of 82 Hemizygous Patients. Invest Ophthalmol Vis Sci, 2016. 57(14): p. 5963-5973.
3. Schulz, H.L., et al, Mutation Spectrum of the ABCA4 Gene in 335 Stargardt Disease Patients From a Multicenter German Cohort-Impact of Selected Deep Intronic Variants and Common SNPs. Invest Ophthalmol Vis Sci, 2017. 58(1): p. 394-403.
4. Garces, F., et al, Correlating the Expression and Functional Activity of ABCA4 Disease Variants With the Phenotype of Patients With Stargardt Disease. Invest Ophthalmol Vis Sci, 2018. 59(6): p. 2305-2315.
Fig. 1.Bland–Altman plots of differences in age at symptom onset across 19 families (A) and best-corrected visual acuity between 13 sibling pairs (B). The central dashed line represents the mean difference and the upper and lower dashed lines, calculated as mean ± 1.96 × SD, represent the upper and lower limits of agreement.
Fig. 2.Bland–Altman plots of differences in age-matched DAF area (A) and radius (B) in the right and left eyes between 13 sibling pairs. The central dashed line represents the mean difference and the upper and lower dashed lines, calculated as mean ± 1.96 × SD, represent the upper and lower limits of agreement.
Fig. 3.Bland–Altman plots of differences in age-matched DAF area (A) and radius (B) growth rates for the right and left eyes between eight sibling pairs. The central dashed line represents the mean difference and the upper and lower dashed lines, calculated as mean ± 1.96 × SD, represent the upper and lower limits of agreement.
Electroretinography Characteristics of the Stargardt Disease Sibling Pairs
| Family No. | Genotype Class | ERG Group | ERG System | Patient No. | Year of Birth | Age at Time of ERG (years) | Discordance in Age at ERG | PERG Abnormal | mfERG Abnormal | ffERG—Cone Dysfunction | ffERG—Rod Dysfunction | ERG Group |
| F1 | B | 3 | LKC | P1 | 1983 | 28 | 11.1 | — | Diffuse | Yes | Yes | 3 |
| 1 | LKC | P2 | 1985 | 17 | Yes | — | No | No | 1 | |||
| F2 | B | 3 | RC | P3 | 1986 | 31 | 6.8 | Yes | Foveal | Yes | Yes | 3 |
| 3 | RC | P4 | 1988 | 24 | No | Foveal | Yes | Yes | 3 | |||
| F3 | A | 3 | RC | P5 | 1977 | 39 | 30.5 | Yes | — | Yes | Yes | 3 |
| 3 | In house | P6 | 1982 | 9 | Yes | — | Yes | Yes | 3 | |||
| F5 | B | 3 | RC | P9 | 1961 | 56 | 3.9 | Yes | Parafoveal | Yes | Yes | 3 |
| 3 | LKC | P10 | 1959 | 52 | Yes | Parafoveal | Yes | Yes | 3 | |||
| F6 | A | 1 | RC | P11 | 2001 | 11 | 3.5 | Yes | — | No | No | 1 |
| 2 | RC | P12 | 2006 | 15 | No | Foveal | Yes | Yes | 2 | |||
| F7 | A | 3 | RC | P13 | 2003 | 10 | 9.5 | Yes | — | Yes | Yes | 3 |
| 3 | RC | P14 | 1994 | 19 | Yes | Diffuse | Yes | Yes | 3 | |||
| F8 | C | 1 | RC | P15 | 1992 | 21 | 2.0 | Yes | Foveal | No | No | 1 |
| 1 | RC | P16 | 1990 | 23 | No | Foveal | No | No | 1 | |||
| F9 | C | 3 | RC | P17 | 1958 | 59 | 11.6 | Yes | Parafoveal | Yes | Yes | 3 |
| 2 | RC | P18 | 1967 | 48 | Yes | — | Yes | No | 2 | |||
| F11 | B | 3 | RC | P21 | 1971 | 47 | 34.1 | Yes | — | Yes | Yes | 3 |
| 1 | In house | P22 | 1977 | 13 | Yes | — | No | No | 1 | |||
| F12 | A | 3 | In house | P24 | 1963 | 26 | 4.4 | — | — | Yes | Yes | 3 |
| 3 | In house | P25 | 1971 | 22 | — | — | Yes | Yes | 3 | |||
| F14 | A | 2 | LKC | P28 | 1993 | 9 | 16.9 | Yes | — | Yes | No | 2 |
| 3 | RC | P29 | 1994 | 26 | Yes | Diffuse | Yes | Yes | 3 | |||
| F15 | C | 2 | RC | P30 | 1937 | 83 | 4.9 | Yes | Diffuse | Yes | No | 2 |
| 1 | RC | P31 | 1942 | 78 | Yes | Parafoveal | No | No | 1 | |||
| F16 | B | 1 | RC | P32 | 1990 | 26 | 3.7 | No | Parafoveal | No | No | 1 |
| 2 | RC | P33 | 1990 | 30 | No | Parafoveal | Yes | Yes | 3 | |||
| F17 | C | 1 | LKC | P34 | 1973 | 32 | 1.1 | Yes | Foveal | No | No | 1 |
| 1 | LKC | P35 | 1978 | 31 | Yes | Foveal | No | No | 1 | |||
| F19 | C | 1 | RC | P38 | 1994 | 20 | 4.3 | No | Foveal | No | No | 1 |
| 1 | LKC | P39 | 1987 | 16 | Yes | — | No | No | 1 |
Definition: Class A, severe biallelic mutations. Class B, an allele of intermediate severity in trans with a severe or intermediate allele. Class C, a mild allele in trans with a severe allele.
Definition: in-house device is a custom-built ERG instrument that used blue light for dim flash scotopic function assessment before 1999, LKC is the UTAS E-3000 system (LKC Technologies, Inc., Gaithersburg, USA) used between 1999 and 2012 and RC (Roland Consult) is the RETIPort 3.2 (Roland Consult, Brandenburg, Germany) used from 2012 onwards.
ffERG, full-field electroretinography; mfERG, multifocal electroretinography; PERG, pattern electroretinography.
Fig. 4.Ultra-widefield fundus autofluorescence images of the right and left eye of siblings from Family 1 (A) and Family 4 (B). In panel A, two male siblings from F1 with a similar age at symptom onset (17 and 16 years) and DAF area (9.6 vs. 8.5 mm2 in the right eye and 11.7 vs. 7.3 mm2 in the left eye) had a discordant age-matched BCVA (6 vs. 33 ETDRS letters in the right eye and 17 vs. 37 ETDRS letters in the left eye). In contrast, panel B shows two male siblings from F4 with a similar BCVA (9 vs. 3 ETDRS letters in the right eye and 8 vs. two ETDRS letters in the left eye) despite large differences in the age-matched DAF area (74.4 vs. 51.4 mm2 in the right eye and 73.4 vs. 44.4 mm2 in the left eye) and DAF radius (4.87 vs. 4.04 mm in the right eye and 4.83 vs. 3.76 mm in the left eye). ETDRS, Early Treatment Diabetic Retinopathy Study.
Fig. 5.Ultra-widefield fundus autofluorescence images of the right and left eyes of siblings from Family 5 ( A) and Family 11 ( B) harboring the same biallelic mutations c.[6079C>T];[4577C>T] with discordant intersibling best-corrected visual acuity (F5) (82 vs. five ETDRS letters in the right eye and 81 vs. 54 ETDRS letters in the left eye) and DAF area (F11) (24.2 vs. 20.9 mm2 in the right eye and 20.7 vs. 14.8 mm2 in the left eye). ETDRS, Early Treatment Diabetic Retinopathy Study.
Fig. 6.Ultra-widefield fundus autofluorescence images of the right and left eyes of siblings from Family 10 ( A) and Family 18 (B) showing a discordance in age at symptom onset with a difference of 14 and >32 years, respectively. In F10, BCVA was hand motions in both siblings at 75 years of age, although the DAF area was significantly greater in the female sibling [A] (55.6 vs. 31.0 mm2 in the right eye and 45.2 vs. 35.5 mm2 in the left eye).
Fig. 7.Ultra-widefield fundus autofluorescence images of the right and left eyes in two discordant mixed sex sibling pairs. In Family 9, the female sibling showed a significantly greater area of DAF area (1.0 vs. 21 mm2 in the right eye and 1.4 vs. 19.4 mm2 in the left eye) despite being 9 years younger than her male counterpart at the time of imaging [A]. In Family 15, an earlier symptom onset in the female sibling (75 vs. 82 years) was noted as compared with her older brother by 7 years [B].